1. Verheugt FW, Granger CB. Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs. Lancet 2015;386:303-10. [DOI:10.1016/S0140-6736(15)60245-8]

2. Di Minno A, Frigerio B, Spadarella G, Ravani A, Sansaro D, Amato M, et al. Old and new oral anticoagulants: food, herbal medicines and drug interactions. Blood Rev 2017;31:193-203. [DOI:10.1016/j.blre.2017.02.001]

3. Garbayo JLM, Castelló IP, Soler MTF, Ribis MP. Hospital admissions for bleeding events associated with treatment with apixaban, dabigatran and rivaroxaban. Eur J Hosp Pharm 2019;26:106-12. [DOI:10.1136/ejhpharm-2017-001390]

4. Heidbuchel H, Vrijens B. Non-vitamin K antagonist oral anticoagulants (NOAC): considerations on once-vs. twice-daily regimens and their potential impact on medication adherence. Europace 2015;17:1317-8. [DOI:10.1093/europace/euv124]

5. Rodriguez R, Carrier M, Wells P. Non‐adherence to new oral anticoagulants: a reason for concern during long‐term anticoagulation? J Thromb Haemost 2013;11:390-94. [DOI:10.1111/jth.12086]

6. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018;39:1330-93. [DOI:10.1093/eurheartj/ehy136]

7. Ten Cate H. New oral anticoagulants: discussion on monitoring and adherence should start now! Thromb J 2013;11:8. [DOI:10.1186/1477-9560-11-8]

8. Haque A, Soundharya R, Venu J, Monika ML, Bakshi V. Method development and validation of apixaban using RP-HPLC method and its stress stability studies. International Journal of Chemical and Pharmaceutical Analysis 2017;5.

9. Byon W, Garonzik S, Boyd RA, Frost CE. Apixaban: a clinical pharmacokinetic and pharmacodynamic review. Clin Pharmacokinet 2019;58:1265-79. [DOI:10.1007/s40262-019-00775-z]

10. Vakkalagadda B, Frost C, Byon W, Boyd RA, Wang J, Zhang D, et al. Effect of rifampin on the pharmacokinetics of apixaban, an oral direct inhibitor of factor Xa. Am J Cardiovasc Drugs 2016;16:119-27. [DOI:10.1007/s40256-015-0157-9]

11. Frost C, Wang J, Nepal S, Schuster A, Barrett YC, Mosqueda‐Garcia R, et al. Apixaban, an oral, direct factor X a inhibitor: Single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol 2013;75(2):476-87. [DOI:10.1111/j.1365-2125.2012.04369.x]

12. Frost C, Nepal S, Wang J, Schuster A, Byon W, Boyd RA, et al. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor X a inhibitor, in healthy subjects. Br J Clin Pharmacol 2013;76:776-86. [DOI:10.1111/bcp.12106]

13. Frost C, Shenker A, Jhee S, Yu Z, Wang J, Bragat A, et al. Evaluation of the single-dose pharmacokinetics and pharmacodynamics of apixaban in healthy Japanese and Caucasian subjects. Clin Pharmacol 2018;10:153-63. [DOI:10.2147/CPAA.S169505]

14. Parys W, Dołowy M, Pyka-Pająk A. Significance of chromatographic techniques in pharmaceutical analysis. Processes 2022;10:172. [DOI:10.3390/pr10010172]

15. Kazakevich YV, Lobrutto R, eds. HPLC for pharmaceutical scientists. Hoboken, New Jersey, United States: John Wiley & Sons; 2007. [DOI:10.1002/0470087951]

16. Dzudovic J, Sakac MC, Antunovic M, Repic A, Obradovic S, Djordjevic S, Savic J, Dzudovic B. Development and validation of LC-MS/MS method for determination of plasma apixaban. Acta Chromatographica 2021;34:332-37. [DOI:10.1556/1326.2021.00948]

17. Lagoutte-Renosi J, Le Poupon J, Girard A, Montange D, Davani S. A simple and fast HPLC-MS/MS method for simultaneous determination of direct oral anticoagulants apixaban, dabigatran, rivaroxaban in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2018;1100-1101:43-49. [DOI:10.1016/j.jchromb.2018.09.026]

18. Baig ML, Ali SA. A validated LC-MS/MS method for the estimation of apixaban in human plasma. Journal of Applied Pharmaceutical Science 2017;7:044-52. [DOI:10.1080/22297928.2017.1333039]

19. Landge SB, Jadhav SA, Dahale SB, Solanki PV, Bembalkar SR, Mathad VT. Development and validation of stability indicating RP-HPLC method on core shell column for determination of degradation and process related impurities of apixaban-an anticoagulant drug. American Journal of Analytical Chemistry 2015;6:539-50. [DOI:10.4236/ajac.2015.66052]

20. Al-Ani I, Hamad M, Al-Shdefat R, Mansoor K, Glogor F, Dayyish WA. Development and validation of stability indicating RP-HPLC method of apixaban in commercial dosage forms. International Journal of Pharmaceutical Sciences and Research 2019;12:241-51.

21. Kashid AM, Vidhate MB, Ingale MR. Analytical method development and validation for estimation of apixaban by RP-HPLC. Indian Drugs 2017;54:76-79. [DOI:10.53879/id.54.04.10680]

22. Akbel E, Bulduk İ, Gökçe S. A green HPLC method for the determination of apixaban in pharmaceutical products: Development and validation. Reviews in Analytical Chemistry 2023;42:20230058. [DOI:10.1515/revac-2023-0058]